In January of this year (2021), Novartis published a phase 2 trial of its interesting drug bimagrumab in people with type 2 diabetes and obesity or overweight. Bimagrumab inhibits an inhibitor of muscle growth, causing muscles to grow. Over 48 weeks, people treated with bimagrumab lost one-fifth of their fat mass and increased their lean mass by 4%, along with notable improvements in blood glucose control.
Versanis Bio secured funding in 2021 to develop bimagrumab for the treatment of obesity.
| Indicator | Value |
|---|---|
| Stars | ★★★☆☆ |
| Platform | Metaculus |
| Number of forecasts | 90 |
In January of this year (2021), Novartis published a phase 2 trial of its interesting drug bimagrumab in people with type 2 diabetes and obesity or overweight. Bimagrumab inhibits an inhibitor of muscle growth, causing muscles to grow. Over 48 weeks,...